The most frequently reported GI adverse events were nausea, diarrhea, vomiting and constipation, with most being mild to moderate in severity
Within each cohort, subjects were randomised to once-daily treatment for 10 weeks with either oral semaglutide tablets (co-formulated with 300 mg SNAC), placebo tablets or placebo tablets with SNAC (300 mg)
Medicare does not cover weight loss medications
Clinicians should engage in shared decision-making discussions with patients, explaining that while there is no official link between tirzepatide and worsening Graves disease, limited specific data exists regarding this patient population
Your doctor may recommend adjusting the dose, implementing structured meal planning, or temporarily pausing dose escalation